INTERACTION OF PUFAS AND DOXORUBICIN: THE ENHANCED TOXICITY IN BREAST CANCER CELLS

被引:2
|
作者
Zajdel, Alicja [1 ]
Wilczok, Adam [1 ]
机构
[1] Med Univ Silesia, Fac Pharmaceut Sci Sosnowiec, Dept Biopharm, Jednosci 8, PL-41200 Sosnowiec, Poland
来源
ACTA POLONIAE PHARMACEUTICA | 2023年 / 80卷 / 05期
关键词
doxorubicin; polyunsaturated fatty acids; eicosapentaenoic acid; docosahexaenoic acid; breast cancer; POLYUNSATURATED FATTY-ACIDS; RESISTANCE;
D O I
10.32383/appdr/171546
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Doxorubicin (DOX) still remains one the most effective clinical drug for breast cancer treatment. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the n-3 polyunsaturated fatty acids (PUFAs), exert pronounced toxicity against many types of cancers including breast cancer. Thus, the authors decided to investigate the mechanism of DOX and PUFAs toxicity on SK-BR-3 and MDA-MB-231 cells. The influence of DOX on PUFA oxidation and effect of DOX and EPA or DHA on cellular metabolic activity, viability, cytotoxicity, apoptosis and oxidative DNA damage in these cells were measured. DOX induced oxidation of the EPA and DHA. Toxicity of DOX and PUFAs towards breast cancer cells was associated with oxidative damage. These PUFAs reduced tested cell growth and caused their death. EPA and DHA potentiated DOX toxic effects through the induction of oxidative DNA damage. The antitumor effect of PUFAs alone and combined with DOX strongly depended on the induction of the oxidative stress that facilitated cell death. The observed changes of DOX toxicity induced by PUFAs suggest the possibility of their application in developing therapeutic anticancer strategies.
引用
收藏
页码:747 / 754
页数:8
相关论文
共 50 条
  • [1] Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
    Wen, Shao-hsuan
    Su, Shey-chiang
    Liou, Bo-huang
    Lin, Cheng-hao
    Lee, Kuan-rong
    CANCER CELL INTERNATIONAL, 2018, 18
  • [2] Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
    Shao-hsuan Wen
    Shey-chiang Su
    Bo-huang Liou
    Cheng-hao Lin
    Kuan-rong Lee
    Cancer Cell International, 18
  • [3] Does insulin make breast cancer cells resistant to doxorubicin toxicity?
    Lykhova, Oleksandra
    Zavelevich, Michael
    Philchenkov, Alex
    Vidasov, Nazar
    Kozak, Tamara
    Lozovska, Yulia
    Andrusyshyna, Iryna
    Bishayee, Anupam
    Borikun, Tetiana
    Lukianova, Natalia
    Chekhun, Vasyl
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (11) : 3111 - 3122
  • [4] Does insulin make breast cancer cells resistant to doxorubicin toxicity?
    Oleksandra Lykhova
    Michael Zavelevich
    Alex Philchenkov
    Nazar Vidasov
    Tamara Kozak
    Yulia Lozovska
    Iryna Andrusyshyna
    Anupam Bishayee
    Tetiana Borikun
    Natalia Lukianova
    Vasyl Chekhun
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 3111 - 3122
  • [5] n-3 PUFAs synergistically enhance the efficacy of doxorubicin by inhibiting the proliferation and invasion of breast cancer cells
    Pradnya Gurav
    Tanvi Patade
    Shubham Hajare
    R. N. Kedar
    Medical Oncology, 41
  • [6] n-3 PUFAs synergistically enhance the efficacy of doxorubicin by inhibiting the proliferation and invasion of breast cancer cells
    Gurav, Pradnya
    Patade, Tanvi
    Hajare, Shubham
    Kedar, R. N.
    MEDICAL ONCOLOGY, 2023, 41 (01)
  • [7] Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer
    Stavridi, Flora
    Palmieri, Carlo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (12) : 1859 - 1869
  • [8] Renal toxicity with liposomal doxorubicin in metastatic breast cancer
    Yemm, Kristyn E.
    Alwan, Laura M.
    Malik, A. Bilal
    Salazar, Lupe G.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (07) : 1738 - 1742
  • [9] Analysis of the Doxorubicin and Doxorubicinol in the Plasma of Breast Cancer Patients for Monitoring the Toxicity of Doxorubicin
    Harahap, Yahdiana
    Ardiningsih, Puspitasari
    Winarti, Agatha Corintias
    Purwanto, Denni Joko
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3469 - 3475
  • [10] Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer
    Ghahremanloo, Atefeh
    Erfani, Bahareh
    Asgharzadeh, Fereshteh
    Mansoori, Saeide
    Gheybi, Fatemeh
    Hashemy, Seyed Isaac
    SCIENTIFIC REPORTS, 2025, 15 (01):